Patents by Inventor Sarah Robertson

Sarah Robertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT FOR CYSTIC FIBROSIS
    Publication number: 20230241045
    Abstract: Compound I of the formula and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.
    Type: Application
    Filed: August 31, 2022
    Publication date: August 3, 2023
    Inventors: Weichao George Chen, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz
  • Methods of treatment for cystic fibrosis
    Patent number: 11517564
    Abstract: Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 6, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Weichao George Chen, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz
  • PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20220257564
    Abstract: A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
    Type: Application
    Filed: September 15, 2021
    Publication date: August 18, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Cathy Chu, Varsha Dhamankar, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz, Weichao George Chen
  • Methods of treatment for cystic fibrosis
    Patent number: 11253509
    Abstract: Compound I of the formula (formula) A pharmaceutically acceptable salt of Compound I. Pharmaceutical compositions containing at least Compound I and methods of treating cystic fibrosis comprising administering at least Compound I. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound I.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: February 22, 2022
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Weichao George Chen, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz
  • Pharmaceutical compositions for treating cystic fibrosis
    Patent number: 11179367
    Abstract: A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: November 23, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Cathy Chu, Varsha Dhamankar, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz, Weichao George Chen
  • Crystalline forms and compositions of CFTR modulators
    Patent number: 11155533
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: October 26, 2021
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • METHODS OF TREATMENT FOR CYSTIC FIBROSIS
    Publication number: 20210113547
    Abstract: Compound I of the formula (formula) A pharmaceutically acceptable salt of Compound I. Pharmaceutical compositions containing at least Compound I and methods of treating cystic fibrosis comprising administering at least Compound I. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound I.
    Type: Application
    Filed: June 8, 2018
    Publication date: April 22, 2021
    Inventors: Weichao George Chen, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz
  • COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20210069174
    Abstract: Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.
    Type: Application
    Filed: June 29, 2018
    Publication date: March 11, 2021
    Inventors: Cathy Chu, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Kirk A. Overhoff, Sarah Robertson, David Waltz
  • CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
    Publication number: 20200392109
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Application
    Filed: March 25, 2020
    Publication date: December 17, 2020
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • METHODS OF TREATMENT FOR CYSTIC FIBROSIS
    Publication number: 20200171015
    Abstract: Methods of treating cystic fibrosis comprising administering at least Compound (I) of the formula. Pharmaceutical compositions containing a pharmaceutically acceptable salt of at least Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of at least Compound (I).
    Type: Application
    Filed: July 17, 2018
    Publication date: June 4, 2020
    Inventors: Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz
  • Crystalline forms and compositions of CFTR modulators
    Patent number: 10654829
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 19, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • METHODS OF TREATMENT FOR CYSTIC FIBROSIS
    Publication number: 20200138798
    Abstract: Compound I of the formula (I) and/or pharmaceutically acceptable salt(s) of Compound I comprised in a pharmaceutical composition and methods of using the same to treat cystic fibrosis.
    Type: Application
    Filed: July 17, 2018
    Publication date: May 7, 2020
    Inventors: Weichao George Chen, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz
  • PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS
    Publication number: 20190240197
    Abstract: A pharmaceutical composition comprising Compound I: Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient.
    Type: Application
    Filed: February 4, 2019
    Publication date: August 8, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Cathy Chu, Varsha Dhamankar, Eleni Dokou, Eric L. Haseltine, Samuel Moskowitz, Sarah Robertson, David Waltz, Weichao George Chen
  • Treatment and diagnosis of infertitlity using TGFbeta or activin
    Publication number: 20060177459
    Abstract: A method of treating an infertility condition in humans or mammals, by exposure of a prospective mother to TGF? or derivative or analog of TGF?. The exposure is advantageously in conjunction with one or more antigens of a prospective father so that a hyporesponsive immune reaction is mounted to the one or more antigens of the prospective father.
    Type: Application
    Filed: April 5, 2006
    Publication date: August 10, 2006
    Applicant: Luminis Pty Ltd.
    Inventors: Sarah Robertson, Kelton Tremellen
  • Treatment and diagnosis of a reproductive disorder by measuring or inhibiting interferon-gamma
    Publication number: 20050272636
    Abstract: The invention provides compositions and methods for diagnosing and treating reproductive disorders. The invention also provides methods for diagnosing reproductive disorders by detecting the presence of IFN-? in the semen of a prospective father, which is indicative of the presence of a reproductive disorder. In particular, the invention provides a method for treating a reproductive disorder in a mammal, comprising administering an effective amount of a compound which inhibits the activity of IFN? to the mammal. The mammal may be the prospective mother or the prospective father.
    Type: Application
    Filed: March 18, 2005
    Publication date: December 8, 2005
    Applicant: Adelaide Research & Innovation Pty Ltd.
    Inventors: Sarah Robertson, David Sharkey, Kelton Tremellen, Danielle Glynn
  • Method and medium for in vitro culture of human embryos
    Publication number: 20040082062
    Abstract: Disclosed is a medium for the propagation of early stage embryos to blastocyst stage. The medium contains an effective amount of human GM-CSF to increase the percentage of pre-blastocyst embryos which develop to transfer ready blastocysts. Also disclosed is a method of growing early stage human embryos to transfer ready blastocysts. The method includes the step of incubating the embryos in vitro in a culture medium containing an effective amount of human GM-CSF for a time and under conditions to increase the proportion of transfer ready blastocysts. An IVF program that includes the method of growing early stage human embryos to transfer ready blastocysts is also disclosed.
    Type: Application
    Filed: July 31, 2003
    Publication date: April 29, 2004
    Inventors: Sarah Robertson, Matts F. Wikland, Cecilia Sjoblom
  • Method and medium for in vitro culture of human embryos
    Patent number: 6605468
    Abstract: Disclosed is a medium for the propagation of early stage embryos to blastocyst stage. The medium contains an effective amount of GM-CSF to increase the percentage of pre-blastocyst embryos which develop to transfer ready blastocysts. Also disclosed is a method of growing early stage human embryos to transfer ready blastocysts. The method includes the step of incubating the embryos in vitro in a culture medium containing an effective amount of human GM-CSF for a time and under conditions to increase the proportion of transfer ready blastocysts. An IVF program that includes the method of growing early stage human embryos to transfer ready blastocysts is also disclosed.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: August 12, 2003
    Assignees: Luminis Pty Ltd., Fertilitescentrum AB
    Inventors: Sarah Robertson, Matts F. Wikland, Cecilia Sjoblom